Digoxin-Grindeks

Digoxin

Method of action: Antiarrhythmic, Cardiac Therapy, Cardiostimulating, Cardiotonic, Cardiovascular Agent

Treatment option: Arrhythmia, Paroxysmal Supraventricular Tachycardia, Heart Failure, Tachycardia, AF

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Digoxin-Grindeks

Quick Facts

Property	Description
Active Ingredient	Digoxin
Forms	Tablets, Solution for Injection
Pharmacological Class	Cardiac Glycoside, Cardiotonic Agent
Common Use	Improving heart function and regulating rhythm
Origin	Semi-synthetic (derived from Digitalis lanata)

What Type of Medicine is Digoxin-Grindeks?

Digoxin-Grindeks is a prescription-only medication whose sole active ingredient is Digoxin, classified as a cardiac glycoside. This specific formulation, produced by Joint Stock Company Grindeks, is supplied as a single-ingredient product. Digoxin belongs to the pharmacological group of cardiotonic agents and antiarrhythmic drugs, which means its primary role is to modulate the heart's pumping function and electrical activity. The compound is historically rooted in the Digitalis lanata plant, leading to its classification as a semi-synthetic compound. Digoxin's dual action—increasing the force of the heart muscle's contractions while also slowing the heart rate—serves to manage patients requiring stable cardiac output. The medicine functions to make the heart beat more strongly and at a more controlled pace.

Composition and Available Forms of Digoxin

The Digoxin-Grindeks preparation consists of the active substance Digoxin (C41H64O14) combined with necessary pharmaceutical excipients required for stable formulation, differentiating it from simple plant extracts. Digoxin is prepared in various key dosage forms, including tablets (often film-coated tablets) intended for oral administration, and a solution for injection for intravenous use. Cardiac glycosides like Digoxin exert their effects via the targeted inhibition of the sodium-potassium pump (Na^+/K^+-ATPase) within myocardial cells. The availability of both the oral form for chronic maintenance therapy and the injectable solution for acute intervention provides options in cardiovascular management, allowing for flexibility in administration depending on the patient's immediate medical requirements.

Regulatory References

What side effects are possible with Digoxin-Grindeks?

Possible side effects and safety information

The safety profile of Digoxin is governed by its narrow therapeutic index, meaning adverse reactions are often linked to higher concentrations in the bloodstream. Official regulatory documents classify potential effects based on the physiological system involved and their documented frequency.

Adverse Reactions by System-Organ Class and Frequency

The most significant safety characteristic is the potential for serious cardiac arrhythmias, which can include ventricular fibrillation and advanced heart block, and may serve as the first sign of toxicity as noted in prescribing information.

Classification	Examples of Documented Effects	System-Organ Class
Common (up to 1 in 10)	Nausea, vomiting, diarrhea, headache, dizziness, visual disturbances, bradycardia (slowed heart rate), and various other arrhythmias.	Gastrointestinal, Nervous system, Eye, Cardiac
Uncommon	Skin rash and pruritus.	Skin and subcutaneous tissue
Rare	Thrombocytopenia (low platelet count).	Blood and lymphatic system
Very Rare	Psychotic episodes, depression, behavioral disturbances, and gynaecomastia.	Psychiatric, Endocrine

Population-Specific Safety Considerations

The safety of Digoxin requires special consideration for specific patient groups, particularly because the drug is primarily cleared by the kidneys. Both older adults and individuals with renal impairment are documented to be at a greater risk of adverse effects due to slower drug elimination leading to accumulation. Furthermore, the official labeling underscores that consistent serum concentration monitoring is a critical restriction to managing exposure and ensuring safety.

Overdose and Emergency Response

Overdose with Digoxin-Grindeks (Digoxin) is a potentially life-threatening event that requires immediate medical attention. The official regulatory profile describes the clinical presentation across multiple body systems.

Documented Overdose Manifestations

Cardiovascular: Potential for nearly all types of arrhythmias, including ventricular tachycardia, ventricular fibrillation, and severe bradycardia.
Gastrointestinal: Common initial signs listed are nausea, vomiting, loss of appetite (anorexia), and abdominal pain.
Neurological/Visual: Symptoms may include confusion, lethargy, headache, and visual disturbances like blurred vision or the perception of yellow halos (xanthopsia).

Required Emergency Actions

Immediate medical help must be sought for any suspected overdose or for the manifestation of severe signs. Urgent treatment and hospitalization are mandated when life-threatening outcomes occur, such as progressive severe bradydysrhythmias or laboratory evidence of severe hyperkalaemia (elevated serum potassium). Management is officially defined as symptomatic and supportive. The specific antidote, Digoxin-specific antibody fragments, is documented for treating severe toxicity. Continuous cardiac monitoring and frequent assessment of serum electrolytes are required procedures during overdose management. Factors like impaired renal function and advanced age are officially noted as increasing the risk of toxicity.

Therapeutic Uses of Digoxin-Grindeks

What Digoxin-Grindeks Treats: Main Uses and Benefits

Digoxin-Grindeks is a specialized treatment generally directed at managing symptoms related to organ-specific functional stress and symptoms associated with acute or episodic changes in rhythm. It is applied in clinical settings where supportive symptom management is appropriate for specific cardiac conditions. The medication is commonly used to provide therapeutic support for patients with symptomatic chronic heart failure and to achieve rate stabilization in specific supraventricular tachyarrhythmias, such as chronic atrial fibrillation.

This medication plays a role in managing conditions where functional stability becomes affected. It is commonly used to help with symptomatic relief across key domains of cardiac conditions.

Symptom Management and Patient Benefit

In heart failure, the medication provides supportive relief relevant for managing symptoms that interfere with daily comfort, which may assist with easing symptoms related to systemic imbalance, such as excessive fatigue and limited exercise capacity, and symptoms related to fluid congestion. In the context of arrhythmias, it is applied to help regulate a rapid, irregular heartbeat, assisting with managing symptoms like palpitations and the sensation of a persistently racing heart. A primary therapeutic goal is supporting the heart in achieving a more controlled pace, which contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Key Symptom Clusters
Focus	Easing symptoms that create noticeable physiological strain and functional stress in the heart.
Benefit	Assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Digoxin-Grindeks?

This section outlines the official eligibility and restrictions for using Digoxin-Grindeks, based strictly on governmental regulatory information.

Contraindicated Populations (Must Not Use)

Digoxin-Grindeks is contraindicated and must not be used by patients who have a known hypersensitivity to digoxin, other digitalis glycosides, or any of the inactive ingredients. It is also strictly prohibited for individuals experiencing ventricular fibrillation or ventricular tachycardia. Patients with supraventricular arrhythmias associated with an accessory atrioventricular (AV) pathway (such as Wolff-Parkinson-White Syndrome) should not use this medicine unless a specialized evaluation has ruled out potential danger.

Restrictions and Special Considerations

Use of Digoxin-Grindeks requires special caution and monitoring in several groups due to an increased risk of toxicity:

Renal Impairment: Because the drug is primarily eliminated by the kidneys, patients with impaired renal function (including many older adults) require significant dose adjustments and careful monitoring.
Age-Related Rules: While used in adults and pediatric patients (including infants), newborns and the elderly are particularly sensitive, often requiring specialized, weight-based dosing.
Condition-Specific Rules: Caution is needed in patients with certain electrolyte imbalances (e.g., low potassium, high calcium), specific types of heart block, hypertrophic obstructive cardiomyopathy, or acute myocardial infarction (where use is generally not recommended). In pregnancy and lactation, use is generally permitted, though the patient must be monitored.

What should I know about interactions with other medicines?

The interaction profile for Digoxin-Grindeks is officially defined by its involvement as a substrate for the P-glycoprotein (P-gp) transporter and its narrow therapeutic window, as detailed in government regulatory documents.

Pharmacokinetic and Exposure-Altering Interactions

Interaction Type	Official Regulatory Statement
Transporter Mechanism	Digoxin is a P-gp substrate. P-gp Inhibitors (e.g., Amiodarone, Verapamil, Quinidine) are documented to increase Digoxin plasma concentrations by reducing its clearance. P-gp Inducers can decrease exposure.
Gastrointestinal	Certain Antibiotics (e.g., Erythromycin) may increase Digoxin exposure in a subset of patients by eliminating gut flora that normally convert the drug to inactive metabolites.

Pharmacodynamic and Substance Interactions

Interaction Type	Official Regulatory Statement
Cardiac Sensitization	Agents that cause Hypokalemia or Hypomagnesemia (e.g., Loop/Thiazide Diuretics) officially increase the heart's sensitivity to Digoxin and the risk of toxicity.
Additive Effects	Co-administration with medications that slow heart conduction (e.g., Beta-blockers) may result in an additive slowing effect on the heart rate. Rapid intravenous Calcium administration is documented to risk serious arrhythmias.
Non-Medicinal Agents	High-fiber foods and specific antacids are officially noted to decrease the total amount of Digoxin absorbed from the gastrointestinal tract. Herbal products like St. John's Wort may reduce its effectiveness.

The interaction structure is determined by classifying agents that modulate P-gp (a pharmacokinetic effect) and those that increase myocardial sensitivity via electrolyte changes (a pharmacodynamic effect). This distinction governs the documented requirements for co-administration restrictions and patient-specific considerations, such as in cases of impaired renal function which reduces clearance and increases exposure.

Mechanism of Action

How Digoxin-Grindeks Works

Molecular Action and Increased Myocardial Force ( Positive Inotropy)

Digoxin initiates its primary action by specifically inhibiting the Na^+/ K^+- ATPase (sodium-potassium pump) enzyme found in the heart muscle cells. This inhibition triggers a molecular cascade that ultimately leads to a net increase in the cell's intracellular calcium ( Ca^2+) stores. This enhanced Ca^2+ availability upon electrical impulse allows for a more forceful interaction between the muscle's contractile proteins, resulting in a stronger force of contraction.

Modulation of Cardiac Electrical Conduction and Rate ( Negative Chronotropy)

The drug's mechanism also extends to modulating the heart's electrical conduction and rate through two simultaneous effects: a direct action that slows conduction, particularly through the atrioventricular ( AV) node, and an indirect effect that enhances parasympathetic nervous system activity (vagal tone). These effects combine to reduce the heart rate and the speed at which electrical signals are conducted, resulting in reduced heart rate and slowed conduction velocity.

Mechanistic Constraints and Electrolyte Sensitivity

Digoxin's binding affinity for the Na^+/ K^+- ATPase is highly sensitive to the concentration of extracellular potassium ( K^+), which acts as a competitive element at the enzyme binding site. This mechanistic relationship means that low K^+ levels can increase the inhibitory effect of Digoxin, placing a critical constraint on the functional scope of the mechanism and its physiological outcomes.

Dosage and Administration Information

Digoxin-Grindeks is administered through two official routes: oral (using tablets or oral solution) and intravenous (IV) injection. The dosing regimen is highly individualized, requiring calculation based on the patient’s age, lean body weight, and especially renal function (creatinine clearance).

Dosing and Administration Protocol

Digoxin therapy generally follows two patterns:

Rapid Digitalization (Loading Dose): For urgent needs, a total calculated dose is given in divided fractions. Approximately half the total dose is administered initially, with the remainder given at 6 to 8-hour intervals (oral) or 4 to 8-hour intervals (parenteral).
Maintenance Dose: The standard long-term regimen is typically once daily. For adults with normal renal function, the usual daily maintenance dose is 0.125 mg to 0.25 mg.

Population-Specific Adjustments

Specific patient groups require individualized dose adjustments:

Population Group	Required Dose Adjustment	Administration Notes
Older Adults (Geriatric)	Often requires a lower starting dose (e.g., 0.125 mg daily).	Caution is necessary due to potential age-related decline in renal function.
Renal Impairment	Requires significant reduction based on estimated creatinine clearance.	Lower doses, such as 0.0625 mg daily or alternate-day dosing, may be needed.
Pediatric Patients	Dosing is calculated strictly on age and body weight; maintenance is often twice daily for infants and young children.	Specialized formulas apply for calculating pediatric loading and maintenance doses.

Contextual Use Instructions

For oral forms, the medicine should be taken at the same time each day. While absorption is usually unaffected by food, taking tablets with high-bran fiber meals may reduce the amount absorbed. The oral solution must be measured using the calibrated dropper or syringe provided with the product. For IV injection, the drug must be administered slowly over at least 5 minutes; bolus injection and mixing with other drugs in the same line are generally not recommended.

Recent Clinical Evidence

Clinical evidence regarding Digoxin focuses primarily on its use in heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AF). Digoxin, a cardiac glycoside, has been the subject of research for centuries, with recent studies examining its long-term safety and efficacy profile in modern care.

Efficacy in Heart Failure (HFrEF)

The landmark DIG (Digitalis Investigation Group) trial in patients with HFrEF in sinus rhythm found that treatment with digoxin did not result in a difference in overall mortality compared to placebo. However, the study did observe that digoxin treatment reduced the rate of hospitalizations due to heart failure.

Evidence in Atrial Fibrillation (AF)

Digoxin is utilized to control the ventricular rate in patients with chronic AF. Research evaluating its association with outcomes in this population is complex, with varying results reported across different studies:

Observational Data: Some retrospective studies and meta-analyses have suggested an association between digoxin use and an increased risk of all-cause mortality, particularly in patients with AF who do not have concomitant heart failure.
Randomized Trials: The smaller RATE-AF trial, involving patients with AF and symptoms of heart failure (mainly with preserved ejection fraction), suggested that low-dose digoxin was comparable to beta-blockers in managing heart rate and improving quality of life.

Safety Considerations

The most commonly reported concern is the drug’s narrow therapeutic window, which necessitates close monitoring of serum concentrations. Evidence suggests that maintaining serum digoxin levels within the range of 0.5 to 0.9 ng/mL may be associated with a more favorable risk profile, while higher concentrations may correlate with an increased risk of adverse events, including cardiac arrhythmias.

Frequently Asked Questions (FAQ)

Common questions about Digoxin-Grindeks (FAQ)

Q: How long does it usually take for Digoxin-Grindeks to start working or for me to feel a difference?

A: According to official patient information, the full clinical effects of Digoxin can take several weeks to develop. If the treatment starts with a regular daily maintenance dose rather than an initial loading dose, it may take several days before effective concentrations are reached in the blood.

Q: Why do doctors often prescribe Digoxin-Grindeks together with a 'water pill' (diuretic)?

A: Diuretics, often called 'water pills,' are commonly prescribed to help manage fluid retention and congestion, which are typical symptoms associated with heart failure. Clinical research that established Digoxin's role in heart treatment often included patients who were already using a diuretic as part of their standard medical care.

Q: What are the most common early side effects to look out for with Digoxin-Grindeks?

A: Official documents list common side effects that often involve the stomach and digestive system. These include loss of appetite, nausea, vomiting, or diarrhea. Other frequently reported effects are headache, weakness, and dizziness.

Q: What is 'Digoxin toxicity,' and how do I recognize the early signs of it?

A: Digoxin toxicity is a form of poisoning caused by having an excessive amount of the medicine in the body. Early signs can include a combination of symptoms such as loss of appetite, confusion, changes in vision (like blurred or yellow vision), and an abnormal or slow heart rate. These symptoms are listed as signs that warrant medical attention.

Q: Can Digoxin-Grindeks cause yellow or blurred vision, and is that a serious sign?

A: Official labeling documents confirm that Digoxin can cause visual disturbances, including blurred vision and, in some cases, seeing objects with a yellow or green tint (xanthopsia). These visual changes are listed as a sign of potential Digoxin toxicity and are symptoms that should be reported to a healthcare provider.

Q: Is it possible for Digoxin-Grindeks to cause an abnormal or slow heart rhythm?

A: Yes, Digoxin is known to affect the heart's electrical system. It can cause a slow heart rate (bradycardia) and various other abnormal heart rhythms. A very slow, fast, or irregular heart rate is also listed in regulatory documents as a potential sign of toxicity.

Q: Is a slow heart rate always a sign of a problem when taking Digoxin-Grindeks?

A: Digoxin is used to help slow the heart rate to improve its efficiency. However, if the heart rate is extremely slow (severe bradycardia) or if it is accompanied by symptoms like confusion or fainting, it may indicate a toxicity issue or another underlying problem. If a slow heart rate occurs, a healthcare provider can evaluate whether the rate is within the expected therapeutic range or if it is excessive.

Q: Can men develop breast swelling (gynecomastia) from long-term use of Digoxin-Grindeks?

A: Gynecomastia (enlarged breasts in males) is a documented, though very rare, side effect of Digoxin. According to official labeling, this effect is sometimes associated with long-term use of the medicine.

Q: What are the main risks of suddenly stopping Digoxin-Grindeks?

A: Official patient advice is clear that the medicine should never be stopped suddenly without first talking to a healthcare provider. Abruptly stopping treatment can lead to a loss of therapeutic benefit, which may result in the worsening of the patient's underlying heart condition.

Q: If I vomit after taking my dose of Digoxin-Grindeks, what should I do?

A: The general guidance for a missed or lost dose (due to vomiting) specifies that a double dose should not be taken. You should skip the dose if the next dose is due within 12 hours and simply take the next scheduled dose at the normal time.

Q: Will Digoxin-Grindeks cure my heart condition, or does it only manage symptoms?

A: Digoxin is officially indicated for the symptomatic management of chronic heart failure and for controlling an irregular heart rhythm. The medicine works to improve the heart's function and manage symptoms, but regulatory documents do not describe the medicine as providing a permanent cure for these chronic conditions.

Q: Why does my doctor need to check my blood levels so often when I take Digoxin-Grindeks?

A: Blood level monitoring is necessary because Digoxin has a narrow therapeutic window. This means there is a very small difference between the amount that is effective and the amount that can cause toxicity. Regular checks ensure the drug concentration stays within the necessary safe and effective range.

Q: What is the target range for Digoxin-Grindeks blood levels?

A: For patients being treated for heart failure, the recommended trough serum concentration range is generally between 0.5 and 0.9 nanograms per milliliter (ng/mL). Maintaining concentrations within this range is associated with a more favorable risk profile than higher concentrations.

Q: Are there any specific over-the-counter pain relievers (like NSAIDs) that should be avoided with Digoxin-Grindeks?

A: Official interaction profiles include warnings regarding certain anti-inflammatory agents, such as Indomethacin. Patients are always required to inform their doctor of all prescription and over-the-counter medicines used due to the drug's broad interaction profile.

Q: What kind of mental changes (like confusion or hallucinations) are possible with Digoxin-Grindeks?

A: Mental changes, including confusion, anxiety, depression, and hallucinations, are documented side effects of Digoxin. These effects are particularly noted as potential signs of drug toxicity or overdose.

Q: Does Digoxin-Grindeks cause weight loss or loss of appetite?

A: Loss of appetite (reduced appetite) is a commonly documented side effect, often listed among other gastrointestinal effects. Official labeling also specifically notes weight loss as a documented adverse reaction in infants and children.

Q: Can I stop taking Digoxin-Grindeks if I feel better, or do I need to keep taking it?

A: Official advice is that consulting a healthcare provider first is necessary, as stopping abruptly may cause symptoms to reappear or the underlying condition to worsen. The medicine should not be stopped suddenly, even if symptoms improve.

Q: If I am having surgery, including dental work, do I need to stop taking Digoxin-Grindeks beforehand?

A: Regulatory documents note that all healthcare providers involved should be informed of current medication use well in advance of any surgery or dental work, as dosage adjustments may be necessary. The dosage may need to be temporarily stopped or reduced before certain medical procedures.

Q: What is the difference between Digoxin-Grindeks and digitoxin?

A: Digoxin and digitoxin are both classified as cardiac glycosides and are used for similar heart conditions. However, they are two separate chemical compounds with differing characteristics in how the body processes and eliminates them, which affects their dosage and side effect profiles.

Q: Why might the brand of Digoxin I take matter to my doctor?

A: Because Digoxin has a narrow therapeutic window, maintaining stable blood concentrations is critical. Differences in the manufacturing process between various generic and brand versions may lead to concerns about how consistently the body absorbs the medicine, making the product's consistency important for safety and effectiveness.

Q: Are there any common cold or allergy medicines that interact with Digoxin-Grindeks?

A: Official patient counseling requires the disclosure of all prescription and over-the-counter (OTC) medicines, including cold and allergy products. This broad warning is given because a wide variety of medications can potentially interact with Digoxin and affect its levels.

Q: Does alcohol consumption interact with Digoxin-Grindeks?

A: Official patient information states that it is unknown if drinking alcohol will directly affect Digoxin blood levels. However, drinking alcohol may increase the risk of known side effects, such as dizziness, blurred vision, and confusion.

Q: Does Digoxin-Grindeks make people feel sleepy or tired?

A: Weakness and feeling tired (fatigue) are documented side effects of Digoxin in the official adverse reaction profiles. These symptoms are also listed as possible signs of drug toxicity.

Q: Can taking Digoxin-Grindeks cause skin rashes or hives?

A: Skin rash is listed as an uncommon side effect of the medicine. Regulatory documents also specifically note the occurrence of hives (urticaria) as a possible sign of an allergic reaction to Digoxin.

Q: Why is it necessary to take Digoxin-Grindeks at the exact same time every day?

A: Taking the medicine at the same time each day is an instruction designed to help maintain a steady blood concentration of Digoxin. This steady level is essential because the medicine has a narrow therapeutic window, meaning consistent timing helps ensure both effectiveness and safety.

Q: Does being underweight increase the risk of side effects from Digoxin-Grindeks?

A: Yes, official prescribing guidelines list low body weight as a risk factor that can potentially predispose a patient to Digoxin toxicity. Dosage calculation for all patients is often determined using the patient's lean body weight.

Q: Is it safe to drive while taking Digoxin-Grindeks?

A: Official patient counseling states that because Digoxin may affect alertness and coordination, patients should avoid driving or operating machinery until they are aware of how the medicine affects them. Digoxin can affect a person's alertness or coordination.

Q: What are the potential interactions between Digoxin-Grindeks and blood pressure medications like ACE inhibitors?

A: Clinical trials used to establish Digoxin's effectiveness in heart failure often included patients who were also taking common blood pressure medications, such as ACE inhibitors. This indicates that co-administration is a common medical practice under a doctor's supervision.

Q: Is it common to take Digoxin-Grindeks for conditions other than heart failure and atrial fibrillation?

A: In addition to its main uses, official indications include the management of certain rapid heart rhythms known as supraventricular tachyarrhythmias. This includes specific uses, such as the management of fetal tachyarrhythmias.

Q: What is the evidence that Digoxin-Grindeks improves quality of life for people with heart failure?

A: Clinical studies have shown that treatment with Digoxin is associated with improvements in functional capacity, such as increased exercise capacity, and a documented reduction in hospitalizations due to worsening heart failure.

How should Digoxin-Grindeks be stored and disposed of?

How to Store and Dispose of Digoxin-Grindeks

Storage and disposal of Digoxin-Grindeks must adhere strictly to the conditions specified on the official regulatory label.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store below 25°C (77°F) (Controlled Room Temperature).
Protection	Must be protected from light and moisture.
Packaging	Keep in the original container and keep it tightly closed.

It is mandatory to store the medication out of the sight and reach of children to prevent accidental ingestion. The product must not be used after the expiry date printed on the carton.

Disposal Instructions

Unused or expired Digoxin-Grindeks must be disposed of through a dedicated drug take-back program or returned to a pharmacy where available. The medication should not be disposed of via wastewater (flushed down the toilet or poured into a drain) to comply with environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.